Tesamorelin 10mg
Modified GHRH analog — 44 amino acids with N-terminal trans-3-hexenoic acid modification Lipophilic modification protects against aminopeptidase degradation in experimental models Research-grade · CAS 218949-48-5 For in vitro GHRH receptor research only
For laboratory research use only. Not for human or veterinary consumption. SKU TSM10.
Product details.
Specifications
| Amino Acids | 44 |
| Modification | N-terminal trans-3-hexenoic acid |
| Molecular Weight | 5135.83 g/mol |
| CAS Number | 218949-48-5 |
| Form | Lyophilized powder |
| Quantity | 10mg per vial |
Three ways to stabilize GHRH
Sermorelin: no modifications, short half-life (~11 min), clean pulsatile release. CJC-1295 No DAC: four amino acid substitutions, moderate half-life (30 min-2 hours). Tesamorelin: full-length sequence with lipophilic N-terminal cap. Three different engineering philosophies applied to the same receptor target. Heritage Labs USA stocks all three.
Research context
Protease assays have confirmed that the trans-3-hexenoic acid group provides effective aminopeptidase resistance. Published studies have examined Tesamorelin in pituitary GHRH receptor signaling, somatotroph response kinetics, and head-to-head comparisons with Sermorelin and CJC-1295.
Frequently paired with
- Ipamorelin 10mg — Available as Ipa/Tesa Blend.
Quality and testing
Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.
Storage
- Lyophilized: -20°C
- Reconstituted: 2-8°C, use within 30 days
For laboratory research use only. Not for human or veterinary use.
FDA Disclaimer. All products are for research use only (RUO) as defined by the FDA — not for diagnostic, human, or veterinary use. These products have not been evaluated and have not been approved by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.
Heritage Labs is a chemical supplier providing products strictly for laboratory research, analytical, and in-vitro purposes; it is not a compounding pharmacy or compounding facility under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act.




